Neffy (epinephrine nasal spray) 1mg is approved for the emergency treatment of type 1 allergic reactions in children aged 4 ...

The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...

Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...

Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 ...

The approval is supported by data from clinical trials, including pharmacodynamic and pharmacokinetic responses in adults and ...

The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for severe allergic reactions and anaphylaxis.

The neffyinSchools program from ARS Pharma will provide eligible public and private K-12 schools in the United States with two cartons of the company’s neffy epinephrine nasal spray, including a ...

During the meeting, ARS Pharmaceuticals will present nine studies showcasing the safety and efficacy of neffy or epinephrine nasal spray, the first FDA-approved needle-free treatment for Type I ...

For patients weighing 15kg to less than 30kg, the recommended dose is 1 spray of neffy 1mg. The Food and Drug Administration (FDA) has approved neffy ® (epinephrine nasal spray) 1mg for the ...